Media coverage about Aquinox Pharmaceuticals (NASDAQ:AQXP) has been trending positive recently, according to Accern. The research group identifies negative and positive media coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Aquinox Pharmaceuticals earned a news sentiment score of 0.27 on Accern’s scale. Accern also gave news articles about the company an impact score of 45.1320314445824 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
Here are some of the news articles that may have effected Accern’s analysis:
Aquinox Pharmaceuticals (AQXP) opened at $15.02 on Thursday. The stock has a market cap of $339.07, a price-to-earnings ratio of -7.78 and a beta of -15.98. Aquinox Pharmaceuticals has a fifty-two week low of $10.02 and a fifty-two week high of $18.49.
A number of research firms recently commented on AQXP. BidaskClub raised shares of Aquinox Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Monday, February 5th. Cantor Fitzgerald reissued a “buy” rating and set a $28.00 target price on shares of Aquinox Pharmaceuticals in a research report on Sunday, February 11th. Guggenheim began coverage on shares of Aquinox Pharmaceuticals in a research report on Thursday, February 8th. They set a “buy” rating and a $26.00 target price for the company. Zacks Investment Research raised shares of Aquinox Pharmaceuticals from a “hold” rating to a “buy” rating and set a $13.00 target price for the company in a research report on Tuesday, January 9th. Finally, Canaccord Genuity set a $22.00 target price on shares of Aquinox Pharmaceuticals and gave the company a “buy” rating in a research report on Monday, December 11th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and four have given a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average target price of $22.80.
ILLEGAL ACTIVITY NOTICE: This piece was published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece on another site, it was stolen and republished in violation of US & international copyright and trademark law. The original version of this piece can be read at https://www.dispatchtribunal.com/2018/02/22/aquinox-pharmaceuticals-aqxp-getting-positive-press-coverage-analysis-shows.html.
Aquinox Pharmaceuticals Company Profile
Aquinox Pharmaceuticals, Inc is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Company’s primary focus is anti-inflammatory product candidates targeting the Src Homology 2 (SH2)-containing inositol-5-phosphatase 1 (SHIP1) enzyme, which is a regulator of a cellular signaling pathway in immune cells, known as the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) pathway.
Receive News & Ratings for Aquinox Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquinox Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.